Product Name :
m-PEG2-Ms
Description:
m-PEG2-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
CAS:
60696-83-5
Molecular Weight:
198.24
Formula:
C6H14O5S
Chemical Name:
2-(2-methoxyethoxy)ethyl methanesulfonate
Smiles :
COCCOCCOS(C)(=O)=O
InChiKey:
FCHYIMQJCGYDPR-UHFFFAOYSA-N
InChi :
InChI=1S/C6H14O5S/c1-9-3-4-10-5-6-11-12(2,7)8/h3-6H2,1-2H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
m-PEG2-Ms is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.|Product information|CAS Number: 60696-83-5|Molecular Weight: 198.24|Formula: C6H14O5S|Chemical Name: 2-(2-methoxyethoxy)ethyl methanesulfonate|Smiles: COCCOCCOS(C)(=O)=O|InChiKey: FCHYIMQJCGYDPR-UHFFFAOYSA-N|InChi: InChI=1S/C6H14O5S/c1-9-3-4-10-5-6-11-12(2,7)8/h3-6H2,1-2H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Atazanavir} MedChemExpress|{Atazanavir} P-glycoprotein|{Atazanavir} Protocol|{Atazanavir} Description|{Atazanavir} custom synthesis|{Atazanavir} Epigenetics} |Shelf Life: ≥12 months if stored properly.{{Miltefosine} web|{Miltefosine} PI3K/Akt/mTOR|{Miltefosine} Protocol|{Miltefosine} In stock|{Miltefosine} custom synthesis|{Miltefosine} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:24318587 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.|References:|An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562Products are for research use only. Not for human use.|
